FI892881A - Förfarande för framställning av terapeutiskt användbara aminosyraderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara aminosyraderivat Download PDF

Info

Publication number
FI892881A
FI892881A FI892881A FI892881A FI892881A FI 892881 A FI892881 A FI 892881A FI 892881 A FI892881 A FI 892881A FI 892881 A FI892881 A FI 892881A FI 892881 A FI892881 A FI 892881A
Authority
FI
Finland
Prior art keywords
preparation
amino acid
acid derivatives
therapeutically useful
useful amino
Prior art date
Application number
FI892881A
Other languages
English (en)
Finnish (fi)
Other versions
FI892881A0 (sv
FI95693C (sv
FI95693B (sv
Inventor
Balraj Krishan Handa
Peter James Machin
Joseph Armstrong Martin
Sally Redshaw
Gareth John Thomas
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888813940A external-priority patent/GB8813940D0/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of FI892881A0 publication Critical patent/FI892881A0/sv
Publication of FI892881A publication Critical patent/FI892881A/sv
Application granted granted Critical
Publication of FI95693B publication Critical patent/FI95693B/sv
Publication of FI95693C publication Critical patent/FI95693C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/06—1,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
FI892881A 1988-06-13 1989-06-13 Förfarande för framställning av terapeutiskt användbara aminosyraderivat FI95693C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB888813940A GB8813940D0 (en) 1988-06-13 1988-06-13 Amino acid derivatives
GB8813940 1988-06-13
GB898908035A GB8908035D0 (en) 1988-06-13 1989-04-10 Amino acid derivatives
GB8908035 1989-04-10

Publications (4)

Publication Number Publication Date
FI892881A0 FI892881A0 (sv) 1989-06-13
FI892881A true FI892881A (sv) 1989-12-14
FI95693B FI95693B (sv) 1995-11-30
FI95693C FI95693C (sv) 1996-03-11

Family

ID=26294009

Family Applications (1)

Application Number Title Priority Date Filing Date
FI892881A FI95693C (sv) 1988-06-13 1989-06-13 Förfarande för framställning av terapeutiskt användbara aminosyraderivat

Country Status (18)

Country Link
US (5) US5157041A (sv)
EP (1) EP0346847B1 (sv)
JP (1) JP2515019B2 (sv)
AU (1) AU624144B2 (sv)
CA (1) CA1340588C (sv)
DE (1) DE68915207T2 (sv)
DK (1) DK172747B1 (sv)
ES (1) ES2052815T3 (sv)
FI (1) FI95693C (sv)
HU (1) HU205898B (sv)
IE (1) IE64495B1 (sv)
IL (1) IL90550A (sv)
MC (1) MC2040A1 (sv)
NO (1) NO175715C (sv)
NZ (1) NZ229480A (sv)
PH (1) PH26082A (sv)
PT (1) PT90836B (sv)
YU (1) YU48068B (sv)

Families Citing this family (152)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
US5614533A (en) * 1987-03-13 1997-03-25 Bio-Mega/Boehringer Ingelheim Research, Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
US5552558A (en) * 1989-05-23 1996-09-03 Abbott Laboratories Retroviral protease inhibiting compounds
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
YU47871B (sh) * 1989-12-11 1996-02-19 F. Hoffman La Roche Ag. Derivati aminokiselina
DE4026614A1 (de) * 1990-08-23 1992-02-27 Bayer Ag Phosphonopyrrolidin- und piperidin-haltige pseudopeptide vom statintyp, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel gegen retroviren
US5475027A (en) * 1990-11-19 1995-12-12 G.D. Searle & Co. Retroviral protease inhibitors
US5583238A (en) * 1990-11-19 1996-12-10 G. D. Searle & Co. Method for making intermediates useful in synthesis of retroviral protease inhibitors
US5614522A (en) * 1990-11-19 1997-03-25 G.D. Searle & Co. Retroviral protease inhibitors
US5648511A (en) * 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
US5475013A (en) * 1990-11-19 1995-12-12 Monsanto Company Retroviral protease inhibitors
ES2151618T3 (es) 1990-11-19 2001-01-01 Monsanto Co Inhibidores de proteasas retrovirales.
US5510487A (en) * 1990-11-19 1996-04-23 G.D. Searle & Co. Retroviral protease inhibitors
US5482947A (en) * 1990-11-19 1996-01-09 Talley; John J. Retroviral protease inhibitors
AU647239B2 (en) * 1991-02-08 1994-03-17 Sankyo Company Limited New beta-amino- alpha-hydroxycarboxylic acids and their use
AU1745092A (en) * 1991-05-10 1992-12-30 Glaxo Group Limited Thiazolidine derivatives and their use in therapy
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
WO1993001174A1 (en) * 1991-07-08 1993-01-21 Glaxo Group Limited Thiazolidine derivatives and their use as anti-viral compounds
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
DE4126485A1 (de) * 1991-08-10 1993-02-11 Bayer Ag Trifluormethyl-haltige pseudopeptide
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
US5491149A (en) * 1991-09-16 1996-02-13 The Du Pont Merck Pharmaceutical Company Dihydroxypropylamine containing retroviral protease inhibitors
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
WO1993013066A1 (en) * 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
US6071895A (en) 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US5679688A (en) 1992-03-11 1997-10-21 Narhex Limited Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
ZA931777B (en) * 1992-03-13 1993-09-23 Bio Mega Boehringer Ingelheim Substituted pyrrolidine derivatives as HIV protease inhibitors.
EP0560268B1 (en) * 1992-03-13 1995-01-04 Bio-Mega/Boehringer Ingelheim Research Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
ATE199545T1 (de) 1992-05-21 2001-03-15 Monsanto Co Inhibitoren retroviraler proteasen
NO932130L (no) * 1992-06-19 1993-12-20 Lilly Co Eli Hemmere av HIV-protease som er nyttige for behandling av AIDS
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
US5968942A (en) * 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5760076A (en) * 1992-08-25 1998-06-02 G.D Searle & Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
AU669223B2 (en) * 1992-08-25 1996-05-30 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
KR100296461B1 (ko) * 1992-08-25 2001-11-14 죤 에이치. 뷰센 레트로바이러스프로테아제저해제로서유용한n-(알카노일아미노-2-히드록시프로필)-술폰아미드
US6022994A (en) 1992-08-25 2000-02-08 G. D. Searle &. Co. Succinoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2123065T3 (es) 1992-08-25 1999-01-01 Searle & Co Hidroxietilamino-sulfonamidas utiles como inhibidores de proteasas retroviricas.
US6046190A (en) * 1992-08-25 2000-04-04 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
US6743929B1 (en) * 1992-08-25 2004-06-01 G. D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5830897A (en) * 1992-08-27 1998-11-03 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
US5783701A (en) * 1992-09-08 1998-07-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US6156768A (en) 1992-10-30 2000-12-05 G. D. Searle & Co. Alpha- and beta-amino acid hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
US5756498A (en) * 1992-10-30 1998-05-26 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
EP0666843B1 (en) * 1992-10-30 1999-08-18 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfamic acids useful as retroviral protease inhibitors
US5578606A (en) 1992-10-30 1996-11-26 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
US6337398B1 (en) 1992-10-30 2002-01-08 G.D. Searle & Co. Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
DE69329544T2 (de) * 1992-12-22 2001-05-31 Eli Lilly And Co., Indianapolis HIV Protease hemmende Verbindungen
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5554653A (en) * 1992-12-22 1996-09-10 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5475136A (en) * 1992-12-22 1995-12-12 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5514801A (en) 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
DK0727419T3 (da) * 1992-12-29 2002-06-10 Abbott Lab Mellemprodukter til fremstilling af forbindelser, som inhiberer retroviral protease
AU6161794A (en) * 1993-01-17 1994-08-15 Schering Corporation Peptides having anti-hiv activity
AU6135294A (en) * 1993-02-12 1994-08-29 Merck & Co., Inc. Piperazine derivatives as hiv protease inhibitors
US5939430A (en) * 1993-02-22 1999-08-17 Merrell Pharmaceuticals Inc. Combinations of retroviral inhibitors
US5455353A (en) * 1993-03-24 1995-10-03 Hoffmann-La Roche Inc. 4-(benzyl-2-oxo-oxazolidin-5 ylmethyl)N tertbutyl-decahydroisoquinoline-3-carboxamides
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5830888A (en) * 1993-04-16 1998-11-03 Monsanto Company Macrocyclic retroviral protease inhibitors
AU6580994A (en) * 1993-04-22 1994-11-08 Yugen Kaisha Libo Method and apparatus for generating fuel gas
WO1994026749A1 (en) * 1993-05-14 1994-11-24 Merck & Co., Inc. Hiv protease inhibitors
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
US5750648A (en) * 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
US5602119A (en) * 1993-10-29 1997-02-11 Vazquez; Michael L. Succinoylamino hydroxyethylamino sulfamic acid derivatives useful as retroviral protease inhibitors
KR0125117B1 (ko) 1994-06-15 1997-12-05 성재갑 항 에이즈(aids)효과를 갖는 신규한 인간 면역 결핍 바이러스(hiv)프로테아제 억제 화합물 및 그의 제조방법
DE69410222T2 (de) * 1993-12-06 1998-09-17 Nippon Kayaku Kk Verfahren zur Herstellung von optisch aktiven Erythro-3-amino-1,2-epoxy-Verbindungen
US6133444A (en) * 1993-12-22 2000-10-17 Perseptive Biosystems, Inc. Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
BR9408531A (pt) * 1994-02-02 1997-08-05 Lilly Co Eli Inibidores da protease hiv e intermediários
TW472047B (en) * 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors
DE69512220T2 (de) * 1994-03-07 2000-03-16 Vertex Pharmaceuticals Inc. Sulfonamidderivate als aspartylprotease-inhibitoren
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
IL114808A (en) * 1994-08-11 1999-10-28 Merck & Co Inc Combinations of protease inhibitors for the treatment of hiv infection and aids
GB2292146A (en) * 1994-08-11 1996-02-14 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS
US5591885A (en) * 1994-09-23 1997-01-07 Hoffman-La Roche Inc. Process for the preparation of halogenated α-aminoketone compounds
US5523463A (en) * 1994-09-23 1996-06-04 Hoffmann-La Roche Inc. Method of producing halogenated and alpha-aminoalchohols
US5481011A (en) * 1994-12-13 1996-01-02 Bristol-Myers Squibb Company Process for preparing N-protected amino acid α-halomethyl ketones and alcohols from N-protected amino acid esters
SK1296A3 (en) * 1995-01-04 1996-08-07 Bayer Ag Acyled pseudopeptides with trifluoromethyl-substituted 2-azabicyklooctane, manufacturing process thereof and medicaments containing these substances
DE19500122A1 (de) * 1995-01-04 1996-07-11 Bayer Ag Neue Pseudopeptide mit trifluormethyl-substituierten 2-Azabicyclooctan
JP4014220B2 (ja) * 1995-01-20 2007-11-28 ジー．ディー．サール アンド カンパニー ビス−スルホンアミドヒドロキシエチルアミノ レトロ ウイルスプロテアーゼインヒビター
US5831117A (en) 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
US5756533A (en) * 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6140505A (en) 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6169085B1 (en) 1995-03-10 2001-01-02 G. D. Searle & Company Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5776971A (en) 1995-03-10 1998-07-07 G.D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US7339078B2 (en) 1995-03-10 2008-03-04 G.D. Searle Llc Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US6667307B2 (en) 1997-12-19 2003-12-23 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) * 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
EP1188766A1 (en) 1995-03-10 2002-03-20 G.D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5985870A (en) * 1995-03-10 1999-11-16 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6407134B1 (en) 1995-03-10 2002-06-18 G. D. Searle & Co. Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
RU2174519C2 (ru) 1995-03-10 2001-10-10 Джи. Ди. Сирл Энд Ко. Гидроксиэтиламино сульфонамиды гетероциклокарбонил аминокислоты, ингибирующие ретровирусную протеазу
US6861539B1 (en) 1995-03-10 2005-03-01 G. D. Searle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
US5693847A (en) * 1995-04-19 1997-12-02 Vertex Pharmaceuticals Incorporated Heteroatom functionalized α-methyl ketones
US6008228A (en) * 1995-06-06 1999-12-28 Hoffman-La Roche Inc. Pharmaceutical compositions containing proteinase inhibitors
US6004957A (en) * 1995-06-07 1999-12-21 Vertex Pharmaceuticals, Incorporated Sulfonamide inhibitors of aspartyl protease
JP3529904B2 (ja) * 1995-06-19 2004-05-24 鐘淵化学工業株式会社 光学活性１−ハロ−３−アミノ−４−フェニル−２−ブタノール誘導体の製造法
DE19531685A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Neue heterocyclisch substituierte Pseudopeptide
WO1997018205A1 (en) * 1995-11-15 1997-05-22 G.D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
EP0774453B1 (en) 1995-11-17 2002-02-06 Ajinomoto Co., Inc. Process for producing 3-amino-2-oxo-1-halogenopropane derivatives
JP2000502332A (ja) * 1995-12-07 2000-02-29 ザ スクリップス リサーチ インスティテュート Ｈｉｖプロテアーゼ阻害剤
US5587481A (en) * 1996-02-20 1996-12-24 The Monsanto Company Preparation of (S)-decahydroisoquinoline-3-carboxylic acid t-butylamide
AU3146997A (en) * 1996-06-03 1998-01-05 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors
US5914404A (en) * 1996-08-09 1999-06-22 Hoffmann-La Roche Inc. Process for the preparation of quinargine
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
DE59709770D1 (de) 1996-12-11 2003-05-15 Hoffmann La Roche Verfahren zur Herstellung gemischter Anhydride
EP0900566A4 (en) * 1996-12-27 2001-04-25 Japan Energy Corp NEW TRIPEPTIDE COMPOUNDS AND MEDICINES AGAINST AIDS
US5846979A (en) * 1997-02-28 1998-12-08 Gpi Nil Holdings, Inc. N-oxides of heterocyclic esters, amides, thioesters, and ketones
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
AU8692698A (en) * 1997-08-06 1999-03-01 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
TR200000291T2 (tr) 1997-08-06 2000-07-21 Eli Lilly And Company Taşikinin reseptör antagonistleri olarak 2-asilaminopropanaminler.
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6803466B1 (en) * 1997-12-08 2004-10-12 The Scripps Research Institute HIV/FIV protease inhibitors having a small P3 residue
WO1999029311A1 (en) * 1997-12-08 1999-06-17 The Scripps Research Institute Hiv/fiv protease inhibitors having a small p3 residue
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6251906B1 (en) 1998-05-15 2001-06-26 Abbott Laboratories Retroviral protease inhibiting compounds
DK1086076T3 (da) 1998-06-19 2005-03-29 Vertex Pharma Sulfonamidinhibitorer af aspartylprotease
EP1095022A1 (en) 1998-07-08 2001-05-02 G.D. Searle & Co. Retroviral protease inhibitors
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
CN1545422B (zh) * 2001-01-17 2010-09-22 罗伯特·H·齐默尔 通过口服和胃肠道外给予含有肽原料药和其它不易吸收的活性成分的组合物来增强药物活性的组合物和方法
US7018642B2 (en) 2001-04-27 2006-03-28 The Procter & Gamble Company Compounds, compositions, and methods for controlling biofilms
US7697966B2 (en) * 2002-03-08 2010-04-13 Sensys Medical, Inc. Noninvasive targeting system method and apparatus
WO2005061487A1 (en) * 2003-12-11 2005-07-07 Abbott Laboratories Hiv protease inhibiting compounds
ATE539074T1 (de) * 2003-12-11 2012-01-15 Abbott Lab Die hiv-protease hemmende verbindungen
US7834043B2 (en) 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
EP1604662A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft 1-[(3R)-Amino-4-(2-fluoro-phenyl)-butyl]-pyrrolidine-(2R)-carboxylic acid benzyl amine derivatives and related compounds as dipeptidyl peptidase IV (DPP-IV) inhibitors for the treatment of type 2 diabetes mellitus
EP1702916A1 (en) * 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
US20070143561A1 (en) * 2005-12-21 2007-06-21 Gorobets Sergey A Methods for adaptive file data handling in non-volatile memories with a directly mapped file storage system
EP2725029A1 (en) 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402969A (en) * 1981-03-23 1983-09-06 Merck & Co., Inc. Antihypertensive proline derivatives
US4470973A (en) * 1982-07-19 1984-09-11 E. R. Squibb & Sons, Inc. Substituted peptide compounds
US4621092A (en) * 1982-07-22 1986-11-04 E. R. Squibb & Sons, Inc. Substituted proline compounds, composition and method of use
US4575503A (en) * 1983-02-10 1986-03-11 Ciba-Geigy Corporation 3-Amino-[1]-benzazepin-2-one-1-alkanoic acids
US4812442A (en) * 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DK34086A (da) * 1985-01-23 1986-07-24 Abbott Lab Peptidylaminodioler
US4638010A (en) * 1985-02-28 1987-01-20 E. R. Squibb & Sons, Inc. Ester substituted aminoalkanoylureido amino and imino acid and ester compounds
US4636522A (en) * 1985-03-22 1987-01-13 E. R. Squibb & Sons, Inc. Acylaminoalkanoyl urethanes or thiourethanes
DE3529960A1 (de) * 1985-08-22 1987-03-05 Boehringer Ingelheim Kg Aminosaeure-derivate, verfahren zu ihrer herstellung und verwendung
AT383762B (de) * 1985-12-23 1987-08-25 Plansee Metallwerk Verfahren zur herstellung mehrkomponentiger, kongruent erschmelzender lotmaterialien
CA1286989C (en) * 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
IL81234A (en) * 1986-01-16 1992-09-06 Abbott Lab Peptidylaminodiols,process for their preparation and pharmaceutical compositions comprising them
NZ218937A (en) * 1986-01-16 1990-03-27 Abbott Lab Functionalised peptidyl aminodiols and -triols as renin inhibitors and pharmaceutical compositions
WO1988000939A1 (en) * 1986-07-25 1988-02-11 Banyu Pharmaceutical Co., Ltd. Optically active amino alcohol derivatives and process for their preparation
DE3789347D1 (de) * 1986-10-14 1994-04-21 Banyu Pharma Co Ltd 5-Substituierte Amino-4-hydroxy-pentansäure-Derivate und deren Verwendung.
US4863905A (en) * 1987-02-04 1989-09-05 Warner-Lambert Company Renin inhibitors II
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE3717631A1 (de) * 1987-05-26 1988-12-15 Merck Patent Gmbh Aminosaeurederivate
DE3733296A1 (de) * 1987-10-02 1989-04-20 Merck Patent Gmbh Aminosaeurederivate
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
IL90218A0 (en) * 1988-05-13 1989-12-15 Abbott Lab Retroviral protease inhibitors
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives

Also Published As

Publication number Publication date
DE68915207D1 (de) 1994-06-16
US5652369A (en) 1997-07-29
DK172747B1 (da) 1999-06-28
FI892881A0 (sv) 1989-06-13
US5157041A (en) 1992-10-20
US5554756A (en) 1996-09-10
DK286389D0 (da) 1989-06-12
IE891879L (en) 1989-12-13
EP0346847A2 (en) 1989-12-20
PH26082A (en) 1992-02-06
DE68915207T2 (de) 1994-08-18
YU120189A (en) 1991-10-31
HU205898B (en) 1992-07-28
JP2515019B2 (ja) 1996-07-10
IE64495B1 (en) 1995-08-09
AU3613089A (en) 1989-12-14
HUT51254A (en) 1990-04-28
NO892407D0 (no) 1989-06-12
FI95693C (sv) 1996-03-11
ES2052815T3 (es) 1994-07-16
PT90836B (pt) 1994-11-30
MC2040A1 (fr) 1990-05-30
IL90550A0 (en) 1990-01-18
AU624144B2 (en) 1992-06-04
EP0346847B1 (en) 1994-05-11
PT90836A (pt) 1989-12-29
IL90550A (en) 1994-01-25
US5446161A (en) 1995-08-29
NO175715C (no) 1994-11-23
US5620987A (en) 1997-04-15
YU48068B (sh) 1996-10-18
NZ229480A (en) 1993-03-26
CA1340588C (en) 1999-06-08
JPH0242048A (ja) 1990-02-13
NO892407L (no) 1989-12-14
DK286389A (da) 1989-12-14
NO175715B (no) 1994-08-15
FI95693B (sv) 1995-11-30
EP0346847A3 (en) 1991-10-23

Similar Documents

Publication Publication Date Title
FI892881A (sv) Förfarande för framställning av terapeutiskt användbara aminosyraderivat
FI97297C (sv) Förfarande för framställning av terapeutiskt användbara boraminosyraderivat
PT87754A (pt) Process for the preparation of new amino acid derivatives
FI890282A0 (sv) Förfarande för framställning av terapeutiskt användbara 23,24-didehydro-25-hydroxikalciferolderivat
FI104170B1 (sv) Förfarande för framställning av terapeutiskt användning 3-aminopyrazolderivat
FI96861C (sv) Förfarande för framställning av terapeutiskt aktiva substituerade indolylpyrrolderivat
FI92934B (sv) Analogiförfarande för framställning av terapeutiskt användbara 1-deoxinojirimycinderivat
FI874459A (sv) Förfarande för framställning av terapeutiskt användbara piperidinderivat
FI101857B1 (sv) Förfarande för framställning av ett nytt terapeutiskt användbart makrocykliskt aminofosfonsyrakomplex
FI850654L (sv) Förfarande för framställning av terapeutiskt användbara pleuromutilinderivator
FI92696C (sv) Förfarande för framställning av terapeutiskt användbara tiazolidindionderivat
FI90877C (sv) Förfarande för framställning av nya terapeutiskt användbara aristeromycin/adenosinderivat
FI883672A (sv) Förfarande för framställning av terapeutiskt användbara aminoalkoxifenylderivat
FI873350A0 (sv) Förfarande för framställning av terapeutiskt användbara 1,4-dihydropyridinderivat
FI892948A0 (sv) Förfarande för framställning av terapeutiskt användbara kromanderivat
FI893003A (sv) Förfarande för framställning av terapeutiskt användbara neplanocinderivat
FI95701B (sv) Förfarande för framställning av terapeutiskt användbara kromanderivat
FI92825C (sv) Förfarande för framställning av terapeutiskt användbara kromanderivat
FI92064C (sv) Förfarande för framställning av terapeutiskt användbara N-bensopyranyllaktamer
FI893002A0 (sv) Förfarande för framställning av terapeutiskt användbara peptidderivater
FI884473A (sv) Förfarande för framställning av terapeutiskt användbara fenoxialkylpyrokatekolderivat
FI892420A (sv) Förfarande för framställning av terapeutiskt användbara 2-aminoetanolderivat
FI890477A (sv) Förfarande för framställning av terapeutiskt användbar 2,5-diamino-6-fluorhexansyra och dess salter
FI863471A (sv) Förfarande för framställning av terapeutiskt användbara 3-desmetylmevalonsyraderivat
PT90273A (pt) Processo para a preparacao de derivados de aminoacidos

Legal Events

Date Code Title Description
BB Publication of examined application
FG Patent granted

Owner name: F. HOFFMANN-LA ROCHE AG